Merck & Co., Inc. (MRK) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 51.08B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 7.14B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 129.80B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $51.08B | (m) | $7.14B | $129.80B | (m) |
| 2026-03-31 | (m) | (m) | (m) | $46.67B | (m) | $5.70B | $128.69B | (m) |
| 2025-12-31 | (m) | (m) | $2.30B | $46.75B | (m) | $14.56B | $136.87B | (m) |
| 2025-09-30 | (m) | (m) | (m) | $39.97B | (m) | $18.21B | $129.55B | (m) |
| 2025-06-30 | (m) | (m) | (m) | $33.97B | (m) | $8.62B | $117.52B | (m) |
| 2025-03-31 | (m) | (m) | (m) | $33.48B | (m) | $9.23B | $115.12B | (m) |
| 2024-12-31 | (m) | (m) | $2.50B | $34.46B | (m) | $13.69B | $117.11B | (m) |
| 2024-09-30 | (m) | (m) | (m) | $34.98B | (m) | $14.59B | $117.53B | (m) |
| 2024-06-30 | (m) | (m) | (m) | $34.72B | (m) | $11.35B | $112.63B | (m) |
| 2024-03-31 | (m) | (m) | (m) | $31.14B | (m) | $5.62B | $105.85B | (m) |
| 2023-12-31 | (m) | (m) | $1.30B | $33.68B | (m) | $7.09B | $106.67B | (m) |
| 2023-09-30 | (m) | (m) | (m) | $33.97B | (m) | $8.77B | $106.73B | (m) |
| 2023-06-30 | (m) | (m) | (m) | $34.07B | (m) | (m) | $104.47B | (m) |
| 2023-03-31 | (m) | (m) | (m) | $28.07B | (m) | (m) | $107.80B | (m) |
| 2022-12-31 | (m) | (m) | $1.70B | $28.75B | (m) | (m) | $109.16B | (m) |
| 2022-09-30 | (m) | (m) | (m) | $28.48B | (m) | (m) | $107.08B | (m) |
| 2022-06-30 | (m) | (m) | (m) | $28.68B | (m) | (m) | $107.09B | (m) |
| 2022-03-31 | (m) | (m) | (m) | $30.59B | (m) | (m) | $106.67B | (m) |
| 2021-12-31 | (m) | (m) | $2.30B | $30.69B | (m) | (m) | $105.69B | (m) |
| 2021-09-30 | (m) | (m) | (m) | $22.91B | (m) | (m) | $93.49B | (m) |
| 2021-06-30 | (m) | (m) | (m) | $24.03B | (m) | (m) | $90.69B | (m) |
| 2021-03-31 | (m) | (m) | (m) | $24.00B | (m) | (m) | $90.85B | (m) |
| 2020-12-31 | (m) | (m) | $2.30B | $25.36B | (m) | $8.06B | $91.59B | (m) |
| 2020-09-30 | (m) | (m) | (m) | $26.32B | (m) | $7.36B | $89.80B | (m) |
| 2020-06-30 | (m) | (m) | (m) | $26.16B | (m) | $11.10B | $90.61B | (m) |
| 2020-03-31 | (m) | (m) | (m) | $21.64B | (m) | $7.43B | $84.91B | (m) |
| 2019-12-31 | (m) | (m) | $1.90B | $22.74B | (m) | $10.45B | $84.40B | (m) |
| 2019-09-30 | (m) | (m) | (m) | $22.68B | (m) | $8.02B | $83.33B | (m) |
| 2019-06-30 | (m) | (m) | (m) | $22.77B | (m) | $7.11B | $83.97B | (m) |
| 2019-03-31 | (m) | (m) | (m) | $22.72B | (m) | $8.80B | $82.35B | (m) |
| 2018-12-31 | (m) | (m) | (m) | $19.81B | (m) | $8.86B | $82.64B | (m) |
| 2018-09-30 | (m) | (m) | (m) | $19.94B | (m) | $10.29B | $85.13B | (m) |
| 2018-06-30 | (m) | (m) | (m) | $19.96B | (m) | $7.59B | $85.04B | (m) |
| 2018-03-31 | (m) | (m) | (m) | $21.50B | (m) | $7.35B | $86.04B | (m) |
| 2017-12-31 | (m) | (m) | $3.00B | $21.35B | (m) | $8.50B | $87.87B | (m) |
| 2017-09-30 | (m) | (m) | (m) | $21.84B | (m) | $11.20B | $91.68B | (m) |
| 2017-06-30 | (m) | (m) | (m) | $21.71B | (m) | $11.97B | $92.80B | (m) |
| 2017-03-31 | (m) | (m) | (m) | $23.44B | (m) | $15.25B | $96.56B | (m) |
| 2016-12-31 | (m) | (m) | $300.00M | $24.27B | (m) | $14.34B | $95.38B | (m) |
| 2016-09-30 | (m) | (m) | (m) | $23.66B | (m) | $13.07B | $98.33B | (m) |
| 2016-06-30 | (m) | (m) | (m) | $23.64B | (m) | $11.83B | $96.47B | (m) |
| 2016-03-31 | (m) | (m) | (m) | $23.66B | (m) | $12.94B | $98.75B | (m) |
| 2015-12-31 | (m) | (m) | $2.30B | $23.93B | (m) | $13.43B | $101.78B | (m) |
| 2015-09-30 | (m) | (m) | (m) | $24.12B | (m) | $12.09B | $101.23B | (m) |
| 2015-06-30 | (m) | (m) | (m) | $24.07B | (m) | $11.37B | $102.58B | (m) |
| 2015-03-31 | (m) | (m) | (m) | $25.51B | (m) | $15.60B | $108.34B | (m) |
| 2014-12-31 | (m) | (m) | $1.00B | $18.70B | (m) | $15.72B | $98.33B | (m) |
| 2014-09-30 | (m) | (m) | (m) | $18.57B | (m) | $14.35B | $101.81B | (m) |
| 2014-06-30 | (m) | (m) | (m) | $18.59B | (m) | $13.39B | $97.86B | (m) |
| 2014-03-31 | (m) | (m) | (m) | $19.59B | (m) | $20.51B | $108.46B | (m) |
| 2013-12-31 | (m) | (m) | $2.10B | $20.54B | (m) | $17.49B | $105.64B | (m) |
| 2013-09-30 | (m) | (m) | (m) | $22.65B | (m) | $18.17B | $106.42B | (m) |
| 2013-06-30 | (m) | (m) | (m) | $22.53B | (m) | $18.10B | $106.88B | (m) |
| 2013-03-31 | (m) | (m) | (m) | $16.09B | (m) | $16.02B | $106.20B | (m) |
| 2012-12-31 | (m) | (m) | (m) | $16.25B | (m) | $16.14B | $106.13B | (m) |
| 2012-09-30 | (m) | (m) | (m) | $17.57B | (m) | $18.12B | $106.30B | (m) |
| 2012-06-30 | (m) | (m) | (m) | $15.06B | (m) | $17.45B | $105.53B | (m) |
| 2012-03-31 | (m) | (m) | (m) | $15.23B | (m) | $15.57B | $105.51B | (m) |
| 2011-12-31 | (m) | (m) | (m) | $15.53B | (m) | $14.97B | $105.13B | (m) |
| 2011-09-30 | (m) | (m) | (m) | $15.69B | (m) | $15.58B | $106.53B | (m) |
| 2011-06-30 | (m) | (m) | (m) | $15.78B | (m) | $13.98B | $106.19B | (m) |
| 2011-03-31 | (m) | (m) | (m) | $15.64B | (m) | $13.03B | $105.86B | (m) |
| 2010-12-31 | (m) | (m) | (m) | $15.48B | (m) | $12.20B | $105.78B | (m) |
| 2010-09-30 | (m) | (m) | (m) | $14.03B | (m) | $10.62B | $107.84B | (m) |
| 2010-06-30 | (m) | (m) | (m) | $13.84B | (m) | $9.94B | $106.17B | (m) |
| 2010-03-31 | (m) | (m) | (m) | $15.28B | (m) | $9.78B | $111.59B | (m) |
| 2009-12-31 | (m) | (m) | (m) | $16.07B | (m) | $9.60B | $112.09B | (m) |
| 2009-09-30 | (m) | (m) | (m) | $8.03B | (m) | (m) | $30.55B | (m) |
| 2009-06-30 | (m) | (m) | (m) | $7.91B | (m) | (m) | $29.55B | (m) |
| 2008-12-31 | (m) | (m) | (m) | $7.93B | (m) | (m) | $28.12B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |